Glioblastoma Multiforme of BrainPhase 1NCT06815432
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
A Phase 1 study testing 15.GPC3-CAR T cells in people with Glioblastoma Multiforme of Brain, run by Baylor College of Medicine at 1 site in United States.
Trial summary
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. Read more about this study
- Who is it for?
- Ages 21 to 70 years
- Conditions the study is for
- Glioblastoma Multiforme of Brain
- What is being tested?
- 15.GPC3-CAR T cells
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Oct 2025to 3 Dec 2044
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Procurement Inclusion Criteria:
- Diagnosis of GPC3-positive recurrent glioblastoma with previous resection planned for repeat resection (as determined by immunohistochemistry).
- Age ≥18 years
- Karnofsky score ≥60%
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent
Procurement Exclusion Criteria:
- History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies).
- History of organ transplantation
- Known HIV positivity
- Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections).
- Exhibits other risk factors of which administration of investigational agent is deemed not in the patient's best interest, in the opinion of the investigator
Treatment Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of GPC3-positive recurrent glioblastoma with previous resection
- Karnofsky score ≥ 60%-
- Stable neurologic exam for 7 days prior to enrollment
- Stable or decreasing dose of steroids over past 7 days prior to surgery and administration of therapy (max allowable dose is 0.1mg/kg dexamethasone or equivalent per day)
- Adequate organ function:
- Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min
- total bilirubin < 3 times ULN for age
- INR ≤1.7
- absolute neutrophil count > 500/μl
- platelet count > 100,000/μl (can be transfused but must be achieved prior to enrollment)
- Hgb ≥ 7.0 g/dl (can be transfused)
- Pulse oximetry >90% on room air
- Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study
- Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion.
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Treatment Exclusion Criteria:
- Pregnancy or lactation
- Uncontrolled infection
- Known HIV positivity
- Active bacterial, fungal or viral infection
- History of organ transplantation
- History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Baylor St. Luke's Medical Center
Houston, Texas, 77030
Ganesh Rao, MD, (713) 798-4696, grao@bcm.edu
About this study
Official title: GPC-3 Chimeric Antigen Receptor T Cells FOR Recurrent GPC-3 Positive Glioblastoma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.
Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T-cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat participants with cancers. They have shown promise, but have not been strong enough to cure most participants.
Read more
The study team has found from previous research that we can put a new gene (a tiny part of what makes-up DNA and carries the participants traits) into T cells that will make them recognize cancer cells and kill them. In the lab, the study team has made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33. The antibody GC33 recognizes a protein found on the participants brain tumor. This CAR is called GPC3-CAR. To make this CAR more effective, the study has also added a gene that includes IL15. IL15 is a protein that helps CAR T cells grow better and stay in the blood longer so that they may kill tumors better. The mixture of GPC3-CAR and IL15 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL15. This study will test T cells with the IL15 GPC3-CAR (GO-CART T cells) in participants with GPC3-positive brain tumors.
T cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. The study team will insert the iCasp9 and IL15 together into the T cells using a virus that has been made for this study. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. The study team will use this drug to kill the T cells if necessary due to side effects.
This study will test T cells genetically engineered with a GPC3-CAR and IL15 (GO-CART T cells) in participants with GPC3-positive brain tumors.
The GO-CART T cells are an investigational product not approved by the Food and Drug Administration.
Read the detailed description
The study team will collect up to 180 mL (approximately 12 tablespoons) of participants blood. This will be used to grow T cells. The study team grows the T cells and uses a retrovirus (a special virus that can insert the GPC3 CAR and IL15 genes into the T cells) to genetically engineer them. After the CAR and IL15 genes were put into the T cells, the study team ensures that they could kill GPC3 positive solid tumor cells in the laboratory.
WHAT THE TREATMENT WILL BE LIKE:
After making these cells, they were frozen. If the participant agrees to participate in this study, at the time they are scheduled to be treated, the cells will then be thawed and administered in the participants tumor area, called an intracavitary or intracerebroventricular administration, during the participants already scheduled surgical resection. The participant will only get one dose of GO-CART T cells. The participant may be pretreated with Tylenol (acetaminophen) and Benadryl (diphenhydramine). Tylenol and Benadryl are given to prevent a possible allergic reaction to the T cell administration.
In addition to the GO-CART T cell treatment, during surgery the surgeon will place a small device called an Ommaya reservoir. This device consists of a small tube approximately 3 millimeters in diameter whose tip will sit in the normal fluid filled spaces in the participants brain (called the ventricles). The other end of the tube will be attached to a small reservoir that will sit underneath the participants scalp. Ommaya reservoirs are commonly placed in cancer participants to treat participants with cancer cells in the cerebrospinal fluid and pose a low risk of complications. The purpose of this reservoir is to help reduce the pressure in the participants brain should they experience this from the treatment which is an unlikely but reported side effect . The reservoir will also be used to monitor the participants response to the study treatment rather than to administer treatment.
This is a dose escalation study, which means that the study team does not know the highest dose of GO-CART T cells that is safe. To find out, the cells will be given to at least 3 participants at a lower dose. If that is safe, the study team will raise the dose level that is given to the next group of participants. The dose a participant received will get will depend on how many participants get the agent before the participant and how they react. The investigator will tell the participant this information. Since the treatment is experimental, what is likely to happen at any dose is not known.
All the treatments will be given by the Center for Cell and Gene Therapy at Baylor St. Luke's Medical Center.
Medical tests before treatment:
Before being treated, the participant will receive a series of standard medical tests:
- Physical exam and history
- Blood tests to measure blood cells, kidney and liver function.
- Pregnancy test (if the participant is a female who can get pregnant)
- If the participant is infected with the hepatitis B virus (HBV) the study team will do a test to measure the levels of the virus
- Measurements of the participants tumor by scans (either CT or MRI). Side effects are rare and include risk of developing an unrelated cancer due to radiation exposure from the machine, but this is unlikely.
Medical tests during and after treatment:
The participant will receive standard medical tests when they are getting the infusions and after:
- Physical exams and History
- Blood tests to measure blood cells, kidney and liver function.
- If the participant is infected with the hepatitis B virus (HBV) the study team will repeat the test and monitor the levels of the virus
- Cerebral spinal fluid collections to monitor for any side effects during the course of the treatment
- Measurements of the participants tumor by scans (1 week, and 4 - 6 weeks after the treatment)
FOLLOW-UP STUDIES:
The study team will follow the participant during and after the injections. To learn more about the way the T cells are working in the participants body, up to 60 mL (up to 12 teaspoons, no more than 3mL/kg/day) of blood will be taken before the chemotherapy, before the T-cell infusion, 1 to 4 hours after the infusion, 3 to 4 days after the infusion (this time point is optional) at 1 week, 2 weeks, 3 weeks, 4 weeks and 8 weeks after the injection, every 3 months for 1 year, every 6 months for 4 years and then every year for the next 10 years. Total participation time for this study will be 15 years.
During the time points listed above, if the T cells are found in the participants blood at a certain amount an extra 5mL of blood may need to be collected for additional testing.
The study team will use this blood to look for the frequency and activity of the cells that have been given ; that is, to learn more about the way the T cells are working and how long they last in the body. The study team will also use this blood to see if there are any long-term side effects of putting the new gene (chimeric antigen receptor, CAR) into the cells. In addition to the blood draws, because the participant has received cells that have had a new gene put in them, they will need to have long term follow up for 15 years to see if there are any long-term side effects of the gene transfer.
Once a year, the participant will be asked to have their blood drawn and answer questions about their general health and medical condition. The study team may ask the participant to report any recent hospitalizations, new medications, or the development of conditions or illness that were not present during enrollment in the study and may request that physical exams and/or laboratory tests be performed if necessary.
If the participants tumor requires further surgery after the study treatment, for clinical reasons the study team will request permission to obtain excess sample to learn more about the effects of the treatment on the participants disease.
In the event of death, the study team will request permission to perform an autopsy to learn more about the effects of the treatment on the participants disease and if there were any side effects from the cells with the new gene.
In addition, the study team will ask for the participants permission to use tumor biopsy for research purposes only. Associated risk with the biopsy will be discussed with the participant in detail in a procedure specific consent form. The study team will test the sample to see if the GO-CART T cells can be found in the tumor and what effect they had on the tumor cells.
If the participant develops a second abnormal cancer growth, significant blood or nervous system disorder during the trial, the study team will request that a biopsy sample of the tissue will be tested.
The remaining blood and/or tissue samples that are not needed directly for the participant could be used to help researchers learn about this disease and/or immune therapy. These specimens and information about the participants circumstances may be shared with other cancer researchers. Although there will be a record identifying under what circumstances these specimens were obtained, under all circumstances the participants identity will be kept confidential. There is a small risk for the loss of confidentiality. However, study personnel will make every effort to minimize this risk. Samples will be kept at Baylor College of Medicine until they are exhausted.
- Conditions
- Glioblastoma Multiforme of Brain
- Being tested
- 15.GPC3-CAR T cells
- Keywords
- GPC3-positive tumors, GPC3-CAR T cells, Glioblastoma, Brain Tumor
- Medical subject headings
- Glioblastoma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
15.GPC3-CAR T cellsGenetic
Four different dosing schedules will be evaluated. The following dose levels will be evaluated:
DL1: 5x10^6 DL2: 1x10^7 DL3: 5x10^7 DL4: 1x10^8
| Study group | Role | What they receive |
|---|---|---|
| 15.GPC3-CAR T cells | Experimental | GPC3-CAR and IL15 will be administered to patients with GPC3-positive glioblastoma. Receives: Genetic: 15.GPC3-CAR T cells |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Patients with Dose Limiting Toxicity
A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the 15.GPC3-CAR T cells. Specifically those which are Grade 5; hematologic dose-limiting toxicity is any Grade 4 non-hematologic toxicity that fails to return to Grade 2 within 72 hours; Grade 4 allergic reaction to CAR T cell administration; Grade 4 \reactions due to CRS and neurotoxicity are rarely seen with the use of CAR-based immunotherapy. Grade 3 cytokine release syndrome (CRS) infusion reactions and neurologic toxicity will only be reported to the FDA if they fail to return to Grade 1 within 72 hours. Grade 4 CRS and neurologic toxicities will be reported to the FDA in an expedited fashion.
Measured: 4 weeks
Secondary outcomes (2)
Response Rate
Response rates will be estimated as the percent of patients whose best response is either complete response or partial by combining the data from lesions recorded via imaging for each patient pre- and post-15.GPC3-CAR T-cell intracavitary administration. These data will be evaluated by iRANO criteria. A 95% confidence interval will be calculated for the response rate.
Measured: 4 weeks
Maximum Tolerated Dose (MTD)
The maximum tolerated dose (MTD) is determined based on isotonic regression as specified in Liu and Yuan (PMID: 3162195). The dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate. If there is no DLT that determine a MTD, the maximum dose level will be declared as the MTD. In case the lowest dose level is determined to be too toxic and the elimination boundary is reached, no MTD will be defined for the trial.
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Feb 2025
- Study start10 Oct 2025
- Primary completion5 Dec 2029 (estimated)
- Study completion3 Dec 2044 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glioblastoma Multiforme of BrainStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Center for Cell and Gene Therapy, Baylor College of Medicine, Baylor St. Luke's Medical Center
- Responsible party
- Principal investigator, Ganesh Rao, MD, Baylor College of Medicine
- Investigators
- Ganesh Rao, MD, Principal investigator, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06815432
- Sponsor's protocol ID
- H-55707 GO-CART
- Status last verified
- Sep 2026
- First submitted
- 4 Feb 2025
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GPC-3 Chimeric Antigen Receptor T Cells FOR Recurrent GPC-3 Positive Glioblastoma
- ClinicalTrials.gov ID
- NCT06815432
- Acronym / sponsor ID
- H-55707 GO-CART
- Conditions
- Glioblastoma Multiforme of Brain
- Keywords
- GPC3-positive tumors, GPC3-CAR T cells, Glioblastoma, Brain Tumor
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Collaborators
- Center for Cell and Gene Therapy, Baylor College of Medicine, Baylor St. Luke's Medical Center
- Study start
- 10 Oct 2025 (actual)
- Primary completion
- 5 Dec 2029 (estimated)
- Study completion
- 3 Dec 2044 (estimated)
- First posted
- 7 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.
Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T-cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat participants with cancers. They have shown promise, but have not been strong enough to cure most participants.
The study team has found from previous research that we can put a new gene (a tiny part of what makes-up DNA and carries the participants traits) into T cells that will make them recognize cancer cells and kill them. In the lab, the study team has made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33. The antibody GC33 recognizes a protein found on the participants brain tumor. This CAR is called GPC3-CAR. To make this CAR more effective, the study has also added a gene that includes IL15. IL15 is a protein that helps CAR T cells grow better and stay in the blood longer so that they may kill tumors better. The mixture of GPC3-CAR and IL15 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL15. This study will test T cells with the IL15 GPC3-CAR (GO-CART T cells) in participants with GPC3-positive brain tumors.
T cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. The study team will insert the iCasp9 and IL15 together into the T cells using a virus that has been made for this study. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. The study team will use this drug to kill the T cells if necessary due to side effects.
This study will test T cells genetically engineered with a GPC3-CAR and IL15 (GO-CART T cells) in participants with GPC3-positive brain tumors.
The GO-CART T cells are an investigational product not approved by the Food and Drug Administration.
Detailed description
The study team will collect up to 180 mL (approximately 12 tablespoons) of participants blood. This will be used to grow T cells. The study team grows the T cells and uses a retrovirus (a special virus that can insert the GPC3 CAR and IL15 genes into the T cells) to genetically engineer them. After the CAR and IL15 genes were put into the T cells, the study team ensures that they could kill GPC3 positive solid tumor cells in the laboratory.
WHAT THE TREATMENT WILL BE LIKE:
After making these cells, they were frozen. If the participant agrees to participate in this study, at the time they are scheduled to be treated, the cells will then be thawed and administered in the participants tumor area, called an intracavitary or intracerebroventricular administration, during the participants already scheduled surgical resection. The participant will only get one dose of GO-CART T cells. The participant may be pretreated with Tylenol (acetaminophen) and Benadryl (diphenhydramine). Tylenol and Benadryl are given to prevent a possible allergic reaction to the T cell administration.
In addition to the GO-CART T cell treatment, during surgery the surgeon will place a small device called an Ommaya reservoir. This device consists of a small tube approximately 3 millimeters in diameter whose tip will sit in the normal fluid filled spaces in the participants brain (called the ventricles). The other end of the tube will be attached to a small reservoir that will sit underneath the participants scalp. Ommaya reservoirs are commonly placed in cancer participants to treat participants with cancer cells in the cerebrospinal fluid and pose a low risk of complications. The purpose of this reservoir is to help reduce the pressure in the participants brain should they experience this from the treatment which is an unlikely but reported side effect . The reservoir will also be used to monitor the participants response to the study treatment rather than to administer treatment.
This is a dose escalation study, which means that the study team does not know the highest dose of GO-CART T cells that is safe. To find out, the cells will be given to at least 3 participants at a lower dose. If that is safe, the study team will raise the dose level that is given to the next group of participants. The dose a participant received will get will depend on how many participants get the agent before the participant and how they react. The investigator will tell the participant this information. Since the treatment is experimental, what is likely to happen at any dose is not known.
All the treatments will be given by the Center for Cell and Gene Therapy at Baylor St. Luke's Medical Center.
Medical tests before treatment:
Before being treated, the participant will receive a series of standard medical tests:
- Physical exam and history
- Blood tests to measure blood cells, kidney and liver function.
- Pregnancy test (if the participant is a female who can get pregnant)
- If the participant is infected with the hepatitis B virus (HBV) the study team will do a test to measure the levels of the virus
- Measurements of the participants tumor by scans (either CT or MRI). Side effects are rare and include risk of developing an unrelated cancer due to radiation exposure from the machine, but this is unlikely.
Medical tests during and after treatment:
The participant will receive standard medical tests when they are getting the infusions and after:
- Physical exams and History
- Blood tests to measure blood cells, kidney and liver function.
- If the participant is infected with the hepatitis B virus (HBV) the study team will repeat the test and monitor the levels of the virus
- Cerebral spinal fluid collections to monitor for any side effects during the course of the treatment
- Measurements of the participants tumor by scans (1 week, and 4 - 6 weeks after the treatment)
FOLLOW-UP STUDIES:
The study team will follow the participant during and after the injections. To learn more about the way the T cells are working in the participants body, up to 60 mL (up to 12 teaspoons, no more than 3mL/kg/day) of blood will be taken before the chemotherapy, before the T-cell infusion, 1 to 4 hours after the infusion, 3 to 4 days after the infusion (this time point is optional) at 1 week, 2 weeks, 3 weeks, 4 weeks and 8 weeks after the injection, every 3 months for 1 year, every 6 months for 4 years and then every year for the next 10 years. Total participation time for this study will be 15 years.
During the time points listed above, if the T cells are found in the participants blood at a certain amount an extra 5mL of blood may need to be collected for additional testing.
The study team will use this blood to look for the frequency and activity of the cells that have been given ; that is, to learn more about the way the T cells are working and how long they last in the body. The study team will also use this blood to see if there are any long-term side effects of putting the new gene (chimeric antigen receptor, CAR) into the cells. In addition to the blood draws, because the participant has received cells that have had a new gene put in them, they will need to have long term follow up for 15 years to see if there are any long-term side effects of the gene transfer.
Once a year, the participant will be asked to have their blood drawn and answer questions about their general health and medical condition. The study team may ask the participant to report any recent hospitalizations, new medications, or the development of conditions or illness that were not present during enrollment in the study and may request that physical exams and/or laboratory tests be performed if necessary.
If the participants tumor requires further surgery after the study treatment, for clinical reasons the study team will request permission to obtain excess sample to learn more about the effects of the treatment on the participants disease.
In the event of death, the study team will request permission to perform an autopsy to learn more about the effects of the treatment on the participants disease and if there were any side effects from the cells with the new gene.
In addition, the study team will ask for the participants permission to use tumor biopsy for research purposes only. Associated risk with the biopsy will be discussed with the participant in detail in a procedure specific consent form. The study team will test the sample to see if the GO-CART T cells can be found in the tumor and what effect they had on the tumor cells.
If the participant develops a second abnormal cancer growth, significant blood or nervous system disorder during the trial, the study team will request that a biopsy sample of the tissue will be tested.
The remaining blood and/or tissue samples that are not needed directly for the participant could be used to help researchers learn about this disease and/or immune therapy. These specimens and information about the participants circumstances may be shared with other cancer researchers. Although there will be a record identifying under what circumstances these specimens were obtained, under all circumstances the participants identity will be kept confidential. There is a small risk for the loss of confidentiality. However, study personnel will make every effort to minimize this risk. Samples will be kept at Baylor College of Medicine until they are exhausted.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 15.GPC3-CAR T cells | Experimental | Genetic: 15.GPC3-CAR T cellsGPC3-CAR and IL15 will be administered to patients with GPC3-positive glioblastoma. |
Who may qualify
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 15.GPC3-CAR T cellsFour different dosing schedules will be evaluated. The following dose levels will be evaluated: DL1: 5x10^6 DL2: 1x10^7 DL3: 5x10^7 DL4: 1x10^8 | Genetic | 15.GPC3-CAR T cells |
Primary outcome
Number of Patients with Dose Limiting Toxicity
Time frame: 4 weeks
A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the 15.GPC3-CAR T cells. Specifically those which are Grade 5; hematologic dose-limiting toxicity is any Grade 4 non-hematologic toxicity that fails to return to Grade 2 within 72 hours; Grade 4 allergic reaction to CAR T cell administration; Grade 4 \reactions due to CRS and neurotoxicity are rarely seen with the use of CAR-based immunotherapy. Grade 3 cytokine release syndrome (CRS) infusion reactions and neurologic toxicity will only be reported to the FDA if they fail to return to Grade 1 within 72 hours. Grade 4 CRS and neurologic toxicities will be reported to the FDA in an expedited fashion.
2 secondary outcomes
Response Rate
Time frame: 4 weeks
Maximum Tolerated Dose (MTD)
Time frame: 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
Related trials for Glioblastoma Multiforme of Brain
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Active, not recruitingPhase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Glioblastoma, Recurrent Glioblastoma
RecruitingPhase 1
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Glioblastoma Multiforme of Brain, Glioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ganesh Rao, MD principal investigator
Baylor College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing 15.GPC3-CAR T cells in people with Glioblastoma Multiforme of Brain, run by Baylor College of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ganesh Rao, MD ((713) 798-4696, grao@bcm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Patients with Dose Limiting Toxicity (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.